{"analyses":[{"ciLowerLimit":"1.69","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.90","estimateComment":"Risk ratio was estimated using a log-binomial regression model and confidence interval was estimated using robust error variance.","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"<.0001","paramType":"Risk Ratio (RR)","paramValue":"2.22","statisticalMethod":"Log-binomial regression model"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.6","upperLimit":"87.4","value":"75.7"},{"groupId":"OG001","lowerLimit":"27.2","upperLimit":"43.0","value":"34.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"213"}],"units":"Participants"}],"description":"ORR was the percentage of participants with an OR per IMWG criteria. For the analysis set of participants from Study C1071003 and COTA, the OR was defined as PR or better (sCR + CR + VGPR + PR). For Study C1071003 and Flatiron Health, OR was defined as PR or better (at least VGPR + PR). sCR: CR \\& normal serum free light chain (sFLC) ratio \\& absence of clonal cells in BMB/BMA by IH, IF, or flow cytometry. CR: negative immunofixation on serum \\& urine, disappearance of any soft tissue plasmacytoma \\& \\<5% plasma cells in BMA, if measured by sFLC only, preceding criteria + normal sFLC ratio. VGPR: Serum \\& urine M-protein detectable by immunofixation but not on electrophoresis; or \\>=90% reduction in serum \\& urine M-protein level \\<100mg/24h. PR: \\>=50% reduction in serum M-protein \\& reduction in 24h urinary M-protein by \\>=90% or \\<200 mg/24h. Analysis was performed using IPTW method to balance participant characteristics among reporting groups.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with TCR MM who initiated elranatamab (PF-06863135) following TCR eligibility in study C1071003 (NCT04649359) were included.","id":"OG000","title":"Study C1071003 Cohort A"},{"description":"Participants with RW TCR MM who initiated standard of care treatment following TCR eligibility between 16-Nov-2015 and 31-Mar-2022 identified from COTA database were included.","id":"OG001","title":"COTA Cohort"}],"paramType":"NUMBER","populationDescription":"Eligible participants from study C1071003 (Cohort A) and RW participants identified from COTA and Flatiron Health databases were included. Here, \"Overall Number of Participants Analyzed\" is the number of participants after application of IPTW method to raw numbers and is different from the actual participants included in the reporting arm.","reportingStatus":"POSTED","timeFrame":"From index date until first documentation of progression, death, or the start of new anticancer therapy (median follow-up of 10.4 months for study C1071003 cohort A, 8.8 months and 7.7 months for COTA and Flatiron Health cohorts)","title":"Objective Response Rate-Comparison Between Elranatamab in Study C1071003 Cohort A and COTA Cohort Using Inverse Probability of Treatment Weights (IPTW) Analysis","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}